Showing 3351-3360 of 5773 results for "".
- Johnson & Johnson Vision’s Acuvue Abiliti Brand Launches Back-to-School Campaign to Address Myopiahttps://modernod.com/news/johnson-johnson-visions-acuvue-abiliti-brand-launches-back-to-school-campaign-to-address-myopia/2481762/Johnson & Johnson Vision, part of Johnson & Johnson MedTech, announced that its Acuvue Abiliti brand is initiating a Back-to-School campaign to inform parents about the growing risk of myopia and encourage them to schedule a comprehensive eye exam for their children ahead of the new schoo
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene
- Vantage Acquires Ophthalmic Surgical Solutionshttps://modernod.com/news/vantage-acquires-ophthalmic-surgical-solutions/2481757/Vantage Surgical Solutions, a provider of mobilized surgical solutions, announced it has acquired Ophthalmic Surgical Solutions (OSS), which specializes in ophthalmic surgical equipment and services. Terms of the deal were not disclosed. According to Vantage, the acquisition c
- Harrow Launches Vigamox in the United Stateshttps://modernod.com/news/harrow-launches-vigamox-in-the-united-states/2481756/Harrow announced the completion of the transfer of the new drug application (NDA) for Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% to the company. Vigamox, which is a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains o
- Shamir Insight Launches 'Driver Intelligence' Lens Technologyhttps://modernod.com/news/shamir-insight-launches-driver-intelligence-lens-technology/2481754/Shamir Insight announced the launch of Driver Intelligence, a lens technology designed to optimize visual performance and deliver superior clarity for drivers any time of the day, enabling safer driving. Shamir Insight worked closely with the Renault
- Okyo Pharma’s OK-101 Will Be Evaluated to Treat Neuropathic Corneal Pain in Study at Tuftshttps://modernod.com/news/okyo-pharmas-ok-101-will-be-evaluated-to-treat-neuropathic-corneal-pain-in-study-at-tufts/2481753/Okyo Pharma, which is developing OK-101 to treat the symptoms of dry-eye disease (DED), announced an agreement with Tufts Medical Center in Boston to conduct a 40-patient, open-label, clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain (NCP)
- HelpMeSee and USAID Partner to Train New Cataract Specialists to Provide Surgical Care for India's Cataract Blindhttps://modernod.com/news/helpmesee-and-usaid-partner-to-train-new-cataract-specialists-to-provide-surgical-care-for-indias-cataract-blind/2481752/HelpMeSee announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has p
- Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United Stateshttps://modernod.com/news/versea-ophthalmics-will-distribute-celularitys-biovance-and-biovance-3l-ocular-products-in-the-united-states/2481750/Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of